Table 2.
Meta-regression results for baseline characteristics difference on cardiac injury biomarkers of more severe vs. less severe of COVID19.
| Between severity | No. study | Coef (exp) | 95% CI | p Value | |
|---|---|---|---|---|---|
| Age (per year older) | 16 | 1.02 | 0.99 | 1.05 | 0.220 |
| Female | 15 | 1.00 | 0.97 | 1.03 | 0.979 |
| Smoking | 5 | 1.05 | 0.97 | 1.14 | 0.160 |
| Diabetes | 12 | 1.01 | 0.99 | 1.04 | 0.324 |
| Hypertension | 12 | 1.02 | 1.00 | 1.03 | 0.030 |
| Cardiovascular diseasea | 13 | 1.02 | 0.98 | 1.06 | 0.337 |
| Coronary heart disease | 7 | 1.01 | 0.97 | 1.06 | 0.460 |
| Cerebrovascular disease | 7 | 1.01 | 0.93 | 1.11 | 0.748 |
| COPD | 8 | 1.14 | 1.00 | 1.29 | 0.052 |
| Chronic kidney disease | 6 | 0.99 | 0.94 | 1.04 | 0.562 |
| Severity definitions | 16 | 1.36 | 0.88 | 2.12 | 0.154 |
Coef = regression coefficients; CIs = confidence intervals. Severity definitions indicate groups are devided by surviors/non-surviors or severe/less severe. Cardiac injury biomarkers are selected in sequence of troponin>CK-MB > myogloblin>NT-proBNP, which indicate that if one study report troponin and CK-MB, we will use troponin as the outcome and use standard mean difference model to pool the data.
a
Seven of which report data on coronary heart disease were also included.